Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study

Not Applicable

Terminated

Conditions: Arthroplasty, Replacement, Hip

Interventions: Device: Restoration ADM X3 Device

Registration Number: NCT01420237

Lead Sponsor: Stryker Orthopaedics

Brief Summary: The purpose of this study is to evaluate the success rate of cementless primary hip replacement with the Restoration® ADM X3® Acetabular System as compared to other primary hip systems in the literature, through absence of femoral head dislocation at 10 years postoperative.

Detailed Description: This study is a prospective, open-label, post-market, non-randomized, multi-center, clinical evaluation of the Restoration® ADM X3® Acetabular System for primary total hip arthroplasty (THA) with a cementless application in a consecutive series of patients who meet the eligibility criteria. The total enrollment goal for the study is 350 cases, all of which will receive the Restoration® ADM X3® Acetabular System. A minimum of 100 cases (within the study population) will receive the Accolade® II Hip Stem. The remaining cases will receive any other compatible Stryker femoral component.

Data in the literature from other primary hip systems and similar dual mobility cups will be used as historical references.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 367

Inclusion Criteria

Patient has signed an IRB/EC approved, study specific Informed Patient Consent Form.
Patient is a male or non-pregnant female, skeletally mature and age 18-75 years at time of study device implantation.
Patient has a diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD).
Patient is a candidate for a primary cementless acetabular replacement.
Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.

Exclusion Criteria

Patient has a Body Mass Index (BMI) ≥ 40.
Patient has an active or suspected latent infection in or about the affected hip joint at time of study device implantation.
Patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device.
Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's disease) leading to progressive bone deterioration.
Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. > 30 days).
Patient requires revision surgery of a previously implanted total hip replacement or hip fusion to the affected joint.
Patient has a known sensitivity to device materials.
Patient is a prisoner.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Restoration ADM X3 Device	Restoration ADM X3 Device	Restoration ADM X3 Device in total hip replacement.

Primary Outcome Measures

Name	Time	Method
Success Rate	10 years postoperative	Defined as absence of postoperative femoral head dislocation.

Secondary Outcome Measures

Name	Time	Method
Harris Hip Score (HHS) Score Improvement From Preoperative Score	pre-op, 6 week, 1,2,3,4,5 years. 7 and 10 years were optional.	The Harris Hip Score (HHS) assesses pain, function, joint deformity and range of motion. Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score of less than or equal to 79 is considered fair-poor. 90-100 = excellent 80-89 = good 70-79 = fair 0-69 = poor
All Cause Revision and Removal Rates of the Restoration ADM X3 Acetabular System	10 years	Revision or removal of any study component.
Patient Satisfaction and Pain: Follow-up Questionnaire	6-10 years	This questionnaire will be used to obtain the following information: * Satisfaction with the hip replacement * Presence of any pain in the study hip * Surgeries performed on the study hip * Any dislocations in the study hip
Radiographic Stability Rates	6 week,1, 2, 3, 4, 5 years	Cases that present with migration of greater than 5 mm in any direction or at least 2 mm radiolucency in all zones will be considered radiographic failures. All cases were assessed for any migration at the 6 week, 1,2,3,4,5 year time points.
Complication Rates for Psoas Impingement and Associated Groin Pain	10 years	Reported occurrence of any participant/hip experiencing groin pain or psoas impingement.
Short Form-12 (SF-12) Improvement From Preoperative Score	preop, 6 week, 1,2,3,4,5 years	The SF-12 Health Survey is a 12-item patient completed questionnaire to measure general health and well-being. It includes a physical and mental status component score; each ranging from 0-100. Low values represent a poor health state and high values represent a good health state.
Lower Extremity Activity Scale (LEAS) Improvement From Preoperative Score	preop, 6 week, 1,2,3,4,5 years	The LEAS is completed by the participant to assess activity level. Activity levels were ordered in terms of intensity from 1 to 18, with 18 indicating the highest activity level.
EQ-5D Index Score Improvement From Preoperative Score	preop, 6 week, 1,2,3,4,5 years	The EQ-5D is a subject-completed questionnaire designed to assess subject health state values. The EQ-5D consists of 2 areas; the EQ visual analogue scale (EQ VAS) and EQ-5D descriptive system. The EQ VAS collects health state values using a 20 cm visual analogue scale with the endpoints labeled best imaginable health state at the top and worst imaginable health state at the bottom, having numeric values of 100 to 0 respectively. The EQ-5D Time Trade-off (TTO) descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/comfort and anxiety/depression. Each dimension has three levels: no problems, some problems and extreme problems. The index values on a scale between -1 (low) and 1 (high) are showing the average health status according to the 5 dimensions: A low score shows worse health, and a high score shows better health.
Percentage of Cases Which Did Not Have Any Component Revised	10 years	The number of hips that did not undergo a removal/revision of any of the hip components.

Trial Locations

Locations (12): Universitatsklinikum Madgeburg A.o.R. Orthopadische Universitatsklinikum Haus 8
🇩🇪
Magdeburg, Sachsen-Anhalt, Germany
The Ottawa Hospital
🇨🇦
Ottawa, Ontario, Canada
St. Cloud Orthopedic Associates
🇺🇸
Sartell, Minnesota, United States
OrthoArizona
🇺🇸
Gilbert, Arizona, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
Syracuse Orthopedic Specialists
🇺🇸
Fayetteville, New York, United States
St. Michael's Hospital
🇨🇦
Toronto, Ontario, Canada
Hospital for Special Surgery
🇺🇸
New York, New York, United States
Covenant Medical Center
🇺🇸
Saginaw, Michigan, United States
Tucson Orthopaedic Institute
🇺🇸
Tucson, Arizona, United States
Arizona Institute for Bone and Joint Disorders
🇺🇸
Phoenix, Arizona, United States
Missouri Orthopaedic Institute
🇺🇸
Columbia, Missouri, United States